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ABSTRACT We present a rate equation model for the TGF-b pathway in endothelial cells together with novel measurements.
This pathway plays a prominent role in inter- and intracellular communication and subversion can lead to cancer, ﬁbrosis vascular
disorders, and immune diseases. The model successfully describes the kinetics of experimental data and also correctly predicts
the behavior in experiments where the system is perturbed. A novel method in this context, simulated tempering, is used to ﬁt the
model parameters to the data. It provides an ensemble of high quality solutions, which are analyzed with clustering methods and
display a hierarchical structure highlighting distinct parameter subspaces with biological interpretations. This analysis
discriminates between different biological mechanisms to achieve a transient signal from a sustained TGF-b input, where one
mechanism is to use a negative feedback to turn the signal off. Further analysis in terms of parameter sensitivity reveals that this
negative feedback loop in TGF-b signaling renders the system global robustness. This sheds light upon the role of the Smad7
protein in this system.
INTRODUCTION
General considerations
Mathematical modeling of signal transduction networks
using rate equations is increasingly attracting attention as a
powerful tool (see, e.g., (1–5)). It is used to simulate the
kinetics of large signaling networks, where one cannot only
rely on biological intuition. In such studies, the aim is to
identify and shed light on the role of key components and
modules. Furthermore, such approaches allow for predicting
quantities not yet measured.
Rate equation modeling involves three major steps:
1. Specify the components and their interactions and set up
the system of equations.
2. Find values for the kinetic parameters from experimental
estimates or by ﬁtting the model to experimental kinetic
data.
3. Analyze the behavior of the model for extracted param-
eter values.
Step 2 often presents the main limitation for a pathway
modeling approach. The systems tend to have many para-
meters where only a few (if any) have values that represent
reliable estimates from experiments. Also, the experimental
kinetic data is typically not sufﬁcient to constrain the
parameter values to a single optimal solution, and multiple
parameter sets can explain the available data. We address this
problem by consistently looking at ensembles of parameter
sets, where these sets subsequently are clustered with
unsupervised methods, providing explanatory insights into
the data and related biological interpretations.
A novel tool in this context is developed to deal with the
optimization of parameters, simulated tempering (ST), which
has previously been used to map out thermodynamical
properties of protein-folding models (6,7). As with any other
Monte Carlo method, ST naturally provides ensembles of
solutions rather than single ones, subject to analysis by
standard clustering techniques.
In this article, we apply the rate equation methodology to
the Transforming Growth Factor b (TGF-b) pathway in
endothelial cells. The members of the TGF-b superfamily are
responsible for many different biological functions, in-
cluding proliferation, differentiation, apoptosis, embryonic
development, and wound healing. Perturbations in the TGF-
b pathway have been detected in several human diseases,
most notably in many forms of cancer, and in ﬁbrotic diseases
of the liver, the kidney, and the lung (8). This pathway is not
too large for modeling, since there are a sufﬁcient number of
measurements available to infer the value of the parameters
available. Neither is it small enough to use visual inspection
or a simple ON/OFF language as means to draw conclusions
about its dynamics and function. We compare the models
both to existing data (9,10) and to novel measurements ﬁrst
presented here. The experiments consist of kinetic (time-
course) measurements after TGF-b stimulation under differ-
ent conditions: untreated cells and three cases in which
different components of the pathway have been perturbed.
Two of the experiments are used to ﬁt the model parameters
and the other two are left as ‘‘blind test’’ experiments. In
addition, we predict the response of the system when varying
the ligand dosage. Thus, we develop a predictive model that
is tested against existing data. Furthermore, we make testable
predictions for further experiments. We also identify, among
other things, a feedback loop (Smad7) as important for
explaining all data sets used and for the stability of the model.
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To our knowledge, this is the ﬁrst time the TGF-b pathway
including regulatory aspects is approached with dynamical
models. Recently, Vilar et al. (5) presented a detailed recep-
tor model for TGF-b signaling, and we will discuss how this
model relates to our simpliﬁed receptor description.
The TGF-b pathway in endothelial cells
The TGF-b signaling pathway in endothelial cells (see Fig.
1 for a simpliﬁed layout) is triggered by the TGF-b protein,
which acts as a ligand, by binding to and activating a
heteromeric complex of type I and type II serine/threonine
kinase receptors. The type I receptor acts downstream of the
type II receptor and the signal is propagated inside the cell as
the activated receptor complex is internalized and binds to
and phosphorylates a protein of the Smad family, called
receptor-regulated Smads or R-Smads (11–13). The R-Smads
include Smad1, Smad2, Smad3, Smad5, and Smad8. The
phosphorylated R-Smads can form complexes with Smad4,
also referred to as Co-Smad (11,12). These complexes move
into the nucleus where they regulate the transcription of
target genes. There is also an inhibitory effect generated by
the inhibitory-Smads (I-Smads), Smad6, and Smad7 (11,12).
The I-Smads negatively regulate the TGF-b signaling
pathway by binding to the receptors and compete with
R-Smads for receptor interaction, by recruiting ubiquitin
ligase to activated receptor complexes and thereby target
the receptor for proteasomal degradation or by recruiting
phosphatases (PP1-a) that inactivate the type I receptor by
dephosphorylation (12–14).
In most cell types, TGF-b signaling is mediated via the
type I receptor activin receptor-like kinase 5 (ALK5). In
endothelial cells, it is also mediated by the similar ALK1
kinase. Endothelial cells make up the endothelium, a single
layer of ﬂattened cells, which are responsible for the for-
mation connective tissues such as blood cells, blood vessels,
etc. Since neovascularization plays a rate-limiting step in
cancer progression, research has frequently been focused on
endothelial cells (15).
The two receptor proteins ALK1 and ALK5 give rise to
two distinct pathways, which in turn induce opposite cellular
functions. The TGF-b/ALK5 pathway induces the phos-
phorylation of Smad2 and Smad3 whereas the TGF-b/ALK1
pathway is responsible for the phosphorylation of Smad1
and Smad5. Moreover, ALK5 inhibits migration and prolif-
eration while ALK1 stimulates these processes (9).
The phosphorylated R-Smads also display different behav-
iors in endothelial cells. It has been shown in Valdimarsdottir
et al. (10) that the negative regulation of Smad1/5 is de-
pendent on some newly synthesized protein and that Smad7
is induced by TGF-b/ALK1 signaling but unaffected by the
TGF-b/ALK5 signaling. An interpretation of this would be
that in endothelial cells, TGF-b induced activated Smad1/5,
together with Smad4, activates the production of Smad7. The
effect of Smad7 on the two pathways is also different. It has
been shown to inactivate the ligand-bound ALK1 receptor. It
can target the activated receptor for an ubiquitin-ligase-
dependent degradation (14,16). Smad7 can also recruit a
phosphatase (PP1-a) to the activated ALK1 receptor and
thus inhibiting further phosphorylation of Smad1/5 (10). It
has been shown that only high levels of Smad7 have an
inhibitory effect on phosphorylated Smad2 (10). This leads
to the conclusion that Smad7 negatively regulates the
phosphorylation of both Smad1/5 and Smad2 but the
strength of the latter interaction is much weaker.
The putative TGF-b-induced negative feedback from
Smad7 is an interesting aspect of the pathway. What is its
purpose? If it is merely to shut off the ALK1 pathway, could
this not be controlled by simpler means, such as in the form
of creation and degradation? These are two main questions
investigated in our computational analysis of the pathway.
MATERIALS AND METHODS
Use of experimental data
Relative concentration levels for phosphorylated Smad1 (PSmad1) and
phosphorylated Smad2 (PSmad2) are estimated from Western blot analysis.
The time-course data sets are from ﬁve different experiments after TGF-b
stimulation, and both novel and existing measurements are used. The data
sets consist of:
I. A nonperturbed experiment (control), where the cells are only stim-
ulated with TGF-b. This new experiment is described below.
II. Cells that are treated with the protein synthesis inhibitor cyclo-
hexamide, which is modeled by completely blocking all protein pro-
duction (10).
FIGURE 1 The TGF-b pathway in endothelial cells. The ligand, TGF-b,
binds to the receptors ALK1 or ALK5, and induces phosphorylation of
Smad1/5 and Smad2, respectively, which in turn form complexes with
Smad4. These complexes move into the nucleus where they control gene
expression. Smad7 expression is induced during this process and negatively
regulates the ALK1 pathway. (In the calculations we have also allowed for a
negative regulation on the ALK5 pathway which is not shown here.)
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III. Cells that are treated with the proteasome inhibitor MG-132, which is
modeled by removing the proteasomal degradation of all proteins (10).
IV. Cells that are treated with the phosphatase inhibitor orthovanadate,
which is modeled by removing the phosphatases from the model (10).
V. An additional nonperturbed experiment, where the dose-response of
phosphorylated Smad1 and Smad2 is measured by varying the amount
of TGF-b (9).
In Experiments I–IV, the concentrations are measured at times 0, 45, 90,
120, 180, and 240 min after TGF-b addition. To investigate the early
dynamics of the pathway, we have also performed additional measurements
of Experiment I at times 0, 5, 15, 30, 45, 60, and 120. The dose-responses, in
Experiment V, are measured after 45 min only. The doses in this experiment
varied from 0 to 5 ng/ml in six steps.
There are many possible ways to ﬁt the model to experimental data, many
of which display nonbiological behavior. To reduce the number of possible
solutions, we ﬁt to more than one set of experimental data. For detailed
studies, we use Experiments I, II, and V for this calibration, whereas the
others are used as blind-test experiments. In this way, the predictive power
of our approach is tested. We also permute the experiments used for
calibration to investigate the effects of such alterations.
Details of new measurements
Kinetics of TGF-b3 induced Smad2 phosphorylation versus
TGF-b3 induced Smad1/5 phosphorylation
Mouse embryonic endothelial cells were stimulated with 1 ng/ml TGF-b3
for different time points before lysis, fractionated by 6% SDS-PAGE and
blotted. As a positive control, 293-cell lysate transfected with either Smad2/
constitutively active ALK5 (PS2) or Smad1/constitutively active ALK1
(PS1) was used. The ﬁlters were incubated with phospho-Smad2 or
phospho-Smad1 antibodies; detection was performed by enhanced chemo-
luminescence.
Ligands and cells and Western blot analysis
Recombinant TGF-b3 was obtained from K. Iwata (OSI Pharmaceuticals,
Melville, NY). All assays were performed with both ligands with essentially
the same results. Recombinant BMP6 was a gift from Dr. K. Sampath (Curis,
Cambridge, MA). Mouse embryonic endothelial cells were cultured and
Western blot analysis was performed as described in Goumans et al. (9) and
shown in Fig. 4 C below.
The model
Our aim is to develop a model versatile enough to be able to explain current
data for the TGF-b pathway in endothelial cells and where the perturbation
experiments described above can be naturally implemented. At the same
time, each individual reaction step should be described as simply as possible
to keep the number of parameters low. To this end, we model the TGF-b
pathway as described in Table 1 (see also Fig. 1). All reactions are assumed
to be reversible and constant production and degradation of all the
nonphosphorylated proteins are allowed for.
Receptor dynamics
We only include the Type I receptors that are explicitly activated by TGF-b,
and do not include receptor internalization and recycling (Fig. 2). This
simplistic description of the receptor dynamics can be compared with a
recently introduced, rather detailed model for the TGF-b receptors, which
takes into account phenomena such as receptor recycling and trafﬁcking (5).
This detailed model is capable of describing different kinds of receptor
responses to extracellular ligand concentrations depending on the situation at
hand. We demonstrate that, regardless of the simpliﬁcations, our receptor
model behaves strikingly similarly to the more complicated model of Vilar
et al. (5), at least as long as only one ligand of the TGF-b superfamily is
present (see Supplementary Material for details). An explanation for this
similarity is that, although our simplistic receptor model has far fewer
parameters, it does include variants of the parameters pinpointed as the most
important ones by Vilar et al. (5), which are determining the ratio of
degradation of the unbound compared to the activated receptor.
Phosphorylation and complex formation
The activated receptors catalyze the phosphorylation of the R-Smads
(Smad1, Smad2), which is described by a Michaelis-Menten formalism.
PSmad1 and PSmad2 can form complexes with Smad4, and the complex
including PSmad1 can move into the nucleus and induce Smad7 production.
We assume a constant volume difference between the cytoplasm and nucleus,
which can be integrated into model parameters and a nucleus concentration
unit, and hence the volumes are not explicitly introduced in the model.
Feedback inhibition
As described above, Smad7 has an inhibitory effect on the signal. This is
modeled by recruitment of the phosphatase PA (PB) to the activated ALK1
(ALK5), which leads to an inactivation of the receptor. Since an ubiquitin
ligase-dependent degradation of the activated receptor leads to a similar
inactivation behavior, we do not account for this process explicitly in the
model.
Formalism
The reactions in Table 1 are implemented with standard rate equations using
deterministic ordinary differential equations (Table 2). This assumes an
ample amount of molecules involved and not to rare events. These
conditions are very likely satisﬁed in the TGF-b case. For all reactions we
use mass action or Michaelis-Menten enzyme kinetics. The complete set of
equations is given in Table 2. As an example, the equation for Smad1
concentration is given by
d½Smad1
dt
¼ p2  p2p3½Smad1
1 p17½PSmad1  p15½Smad1½TA1
p161 ½Smad1 ; (1)
which can be deduced from rows i and l in Table 1 (see Fig. 1). [X] denotes
the concentration of molecule X and the p-values are kinetic parameters. We
have chosen to use the parameterization rð1 1l ½XÞ for the production and
degradation terms where r and l correspond to the production rate and the
equilibrium level for the production/degradation terms, respectively. These
equilibrium levels are also used as initial concentrations in the simulations.
Computational procedures
We use a general computational procedure that can be divided into
calibration and analysis (see Fig. 3). In the calibration part, we extract
parameter value sets that describe experimental data well, which results in an
ensemble of solutions. The calibration consists of two parts:
1. Optimization, where the parameters are adjusted for the model to ﬁt the
experimental data.
2. Filtering, where good solutions from the optimization procedure are
evaluated against other experimental knowledge.
These procedures require multiple simulations of the model, where the
result of the numerical integration of the ordinary differential equations
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(ODEs) is compared with the experimental data. In the analysis part, we
investigate the behavior of the solutions following from the calibration step.
As a ﬁrst step, the solutions are grouped by clustering. The resulting
subgroups are further evaluated by examining the group-averaged behavior.
In a validation step, the solution behavior is compared with blind-test
experiments, where the predictive power of the solutions is investigated.
Also, we analyze how robust the solutions are with respect to perturbation of
the parameters.
Solving the system of ordinary differential equations
The efﬁciency of the differential equation solver is extremely important
since this is where most computational time is spent, in particular since the
equations are often stiff. We use a procedure that adaptively switches
between two methods to minimize the computational load:
1. Fifth-order Runge-Kutta method, where the step size is varied to keep
the local truncation error constant, using an embedded fourth-order
method to estimate the truncation error; and
2. The Rosenbrock method, which is an implicit method that uses the same
kind of step-size control as Method 1, but is more efﬁcient in the regions
of parameter space where the ODEs become stiff.
Both methods are described in Press et al. (17) and initial parameter values
and other details in this procedure can be found in the Appendix.
Calibration
In the optimization procedure, we estimate the parameters of the model by
ﬁtting to experimental data. After each solution to the ODEs in the iterative
process, the K parameters p¼ (p0,. . .,pK1) are adjusted such that the model
should more accurately describe the experimental data. The latter consist of
N discrete time points t1; t2; . . . tN for each experiment. As error measure, the
quadratic difference is used,
RðpÞ ¼ 1
N
1
M
+
tN
t¼t1
+
M
i¼1
ðxiðt; pÞ  x˜iðtÞÞ2; (2)
where xi(t, p) and x˜iðtÞ denote model points and experimental points,
respectively, and the index i denotes the different molecules (M in total). We
TABLE 1 The different reactions in the TGF-b pathway model, where pi (i ¼ 0,1,. . .,32) are the rate constants
; E*
p0
p0p1
ALK1 ðaÞ ; E*
p2
p2p3
Smad1 ðiÞ
; E*
p4
p4p5
Smad4 ðbÞ ; E*
p6
p6p7
Smad2 ðjÞ
; E*
p8
p8p9
ALK5 ðcÞ ; E*
PS14N
ðp11 ;p12Þ
p10
Smad7 ðkÞ
TGFb1ALK1 E*
p13
p14
TA1 ðdÞ
Smad1 E*
TA1
ðp15 ;p16Þ
p17
PSmad1 ðlÞ
PSmad11 Smad4 E*
p18
p19
PS14 ðeÞ
Smad2 E*
TA5
ðp22 ;p23Þ
p24
PSmad2 ðmÞ
TGFb1ALK5 E*
p20
p21
TA5 ðfÞ PSmad21 Smad4 E*
p25
p26
PS24 ðnÞ
PA1TA1 E*
Smad7
P27
p28
TA1P ðgÞ PS14 E*
p29
p30
PS14N ðoÞ
PB1TA5 E*
Smad7
P31
p32
TA5P ðhÞ
Reactions with the symbol ; model production and degradation. In reactions (k), (l), and (m), Michaelis-Menten dynamics is used.
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use two experiments in the optimization procedure, and the sum of the two R
values is used as error measure. To ﬁnd good approximate solutions to
global minima for Eq. 2, one can use Monte Carlo methods like simulated
annealing (18). Here, we employ a related but more powerful method,
simulated tempering (ST) (6,7), where the ﬁctitious temperature is a
dynamic variable, and the system is always kept at equilibrium for the
different temperatures. Solutions are obtained by ‘‘quenching’’ from the
lowest temperature to T¼ 0 corresponding to a local search. The underlying
idea is to scan sizable parts of the solution space at different high
temperatures and regularly visit low temperature solutions. In a sense, this
optimization method corresponds to simulated annealing with multiple
random starts and it yields ensembles of solutions rather than single ones.
The details of the ST implementation are found in the Appendix.
To further restrict the behavior of solutions included in the analysis, we
select solutions from the optimization step to correctly describe the dosage
Experiment V. We run the model for different dosages of TGF-b and
calculate a measure similar to R (see Appendix for details). Finally, a small
subset of these solutions is removed based on an overﬁtted behavior. (Note
that a small number—four—of the solutions display a high-order behavior in
the simulations. Although these solutions do get a good R-value, the behavior
does not ﬁt the experiments well if the concentration levels are assumed to
interpolate smoothly between the measurements. These solutions are
removed by inspection, but could have been removed by, e.g., using a
criteria of not allowing for multiple peaks. If these solutions are included in
the analysis, they cluster with the group not using the feedback. The group
behavior is not altered signiﬁcantly, but the sensitivity and the variation in the
predictions are slightly increased.)
Solution properties
To investigate properties and interior structures of the solution space, we use
three different methods:
1. Hierarchical clustering.
2. K-means clustering.
3. Principal component analysis (PCA).
Before this analysis, the data is preprocessed to obtain a distribution for each
parameter with mean of 0 and standard deviation of 1 (for details on the
implementation, see the Appendix).
Robustness
A common method used to analyze the robustness of a system is to use the
derivatives of the molecule concentrations, xi(t, p), with respect to the
different parameters, p, as a direct measurement of the sensitivity of the
system (20). We deﬁne a sensitivity vector according to
sj[
pj
M
+
M
i¼1
+
N
k¼1
1
xiðtk;pÞ
@xiðtk;pÞ
@pj
jp0
 2 !1=2
; (3)
where the derivative is approximated by a simple ﬁnite-difference approx-
imation, using 1% parameter variations.
RESULTS
Calibration
First, we generate an ensemble of solutions from ﬁtting to the
control (I) and cyclohexamide (II) experiments. Good
solutions are selected with the criteria R , 0.01 yielding
;200 solutions. As can be seen from Fig. 4, these solutions
ﬁt both experiments well. Hence the parameterization form is
appropriate and the optimization method efﬁcient. Next, we
select for those solutions that at the same time successfully
describe the saturated behavior at different TGF-b dosages
(Experiment V). An ensemble of 38 solutions pass this
ﬁltering step (see Fig. 5), from which four are removed based
on an overﬁtting criteria (see end of Calibration, above). The
remaining 34 solutions are used for further investigations.
Solution properties
Individual parameter values vary considerably in the
calibration solution set, most with ranges of several orders
of magnitude. To analyze the homogeneity of the solutions
we cluster the ensemble of parameter sets using different
clustering algorithms and distance measures. The result for
hierarchical clustering with a Pearson correlation distance
measure is shown in Fig. 6 A, where two main groups can be
identiﬁed. K-means clustering with K ¼ 2 also results in a
similar grouping. Fig. 6 B shows the K-means result
projected onto the two main directions from a principal
component analysis. As will be shown in a more detailed
analysis, the two groups of solutions deﬁne two very distinct
biological interpretations of how the PSmad1 signal is made
transient in the case of a sustained TGF-b input: All the
group-2 solutions use the putative Smad7 feedback loop,
while the solutions of group 1 do not. This division of the
solutions is very robust to a variety of settings in the clus-
tering algorithms. Occasionally, a small set of the solutions
emerge as outliers, and two of the solutions also end up in
different clusters depending on method (compare Fig. 6, A
and B). Although our analysis does not depend upon the
FIGURE 2 Simpliﬁed receptor model. The ligand TGF-
b binds to a type I receptor (ALK1 or ALK5) and forms an
active complex that mediates the signal via the phospho-
rylation of R-Smads. The active receptors are inactivated
by Smad7, which recruits phosphatases to the active
receptors. We also allow for a constant production and
degradation of the inactive receptors.
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assignment of these two solutions, we choose not to include
them in the further analysis. The parameter values for these
32 solutions are provided in Supplementary Material.
We also performed clustering on a subset of the solutions
that do not correctly describe the dose-response experiment,
but still satisfy R , 0.01. In this case, we get equivalent
results, with two distinct groups with the same difference in
biologically interpretable behavior with one group using the
Smad7 feedback loop, whereas the other group does not
(data not shown).
Prediction
The solutions that were clustered were chosen to accurately
predict the dosage experiment (Fig. 5). To further analyze the
predictive power of the two deﬁned ensembles of solutions
we have performed two blind-test experiments: Cells treated
with the proteasome inhibitor MG-132 (III) and phosphatase
inhibitor orthovanadate (IV), respectively. In Fig. 7, the
model predictions from group 1 and group 2 are shown and
compared with experiments, again for levels of PSmad1 and
PSmad2. As can be seen, the PSmad2 levels are not affected
signiﬁcantly in either of the perturbed systems as compared
to the control experiment (Fig. 4 A). This behavior is
accurately predicted by both groups of solutions. In the MG-
132 experiment (see Fig. 7 A), the PSmad1 signal still
appears transient although the peak is broadened in time.
Both groups of solutions predict a transient PSmad1 signal
very similar to the behavior of the control experiment in this
case. This lack of broadening of the peak for all solutions is
discussed in more detail below, where we do optimization on
control and MG-132.
It is in the PSmad1 behavior in the orthovanadate exper-
iment (see Fig. 7 B) where the predictions from two groups
distinctly differ. In this case, group 1 predicts a transient
PSmad1 signal very similar to the behavior in the control
experiment, whereas group 2 predicts a more sustained signal
TABLE 2 Model equations of the TGF-b pathway
dA1
dt
¼ p0ð1 p1A1Þ  p13TbA11 p14T1
dS1
dt
¼ p2ð1 p3S1Þ  p15T1S1
p161 S1
1 p17P1
dS4
dt
¼ p4ð1 p5S4Þ  p18P1S41 p19P14  p25P2S41 p26P24
dS2
dt
¼ p6ð1 p7S2Þ  p22T1S2
p231 S2
1 p24P2
dA5
dt
¼ p8ð1 p9A5Þ  p20TbA51 p21T5
dS7
dt
¼ p11P14
p121P14
 p10S7
dP1
dt
¼ p15T1S1
p161 S1
 p17P1  p18P1S41 p19P14
dP14
dt
¼ p18P1S4  p19P14  p29P141 p30P14N
dP14N
dt
¼ p29P14  p30P14N
dP2
dt
¼ p22T1S2
p231 S2
 p24P2  p25P2S41 p26P24
dP24
dt
¼ p25P2S4  p26P24
dT1
dt
¼ p13TbA1  p14T1  p27S7PAT11 p28T1P
dT5
dt
¼ p20TbA5  p21T5  p31S7PBT51 p32T5P
dPA
dt
¼ p27S7PAT11 p28T1P
dPB
dt
¼ p31S7PBT11 p32T1P
dT1P
dt
¼ p27S7PAT1  p28T1P
dT5P
dt
¼ p31S7PBT5  p32T5P
The abbreviations used are: Si ¼ [Smadi] i ¼ 1, 2, 4, 7; A1 ¼ [ALK1]; A5 ¼
[ALK5]; Tb ¼ [TGFb]; P1 ¼ [PSmad1]; P2 ¼ [PSmad2]; T1 ¼ [TA1]; T5 ¼
[TA5]; T1P ¼ [TA1P]; T5P ¼ [TA5P]; PA ¼ [phosphatase A] (responsible
for the inhibition of the ALK1 pathway); and PB ¼ [phosphatase B]
(responsible for the inhibition of the ALK5 pathway).
FIGURE 3 Flowchart of the calibration and validation process. Solutions
are found in two steps; optimization followed by an independent test of the
solutions against dose response tests. The solutions surviving these two steps
are then clustered, which results in two distinct groups displaying different
behavior. Group 1 does not use the Smad7 feedback loop whereas group
2 does. The numbers on the right-hand side show the number of solutions
in the different steps.
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in closer agreement with the experimental values. This exper-
iment (and model perturbation) mainly affects the feedback
from Smad7 by disabling the phosphatase to inactivate the
activated ALK1 receptor, and the behavior of group 1 in this
case indicates that these solutions do not use the feedback
loop.
It should be noted that these experiments are quite crude
and may affect the cells in ways not feasible to include in our
model, which is restricted to the molecules directly involved
in the TGF-b pathway. A much more direct experiment for
model prediction would be to perturb a single speciﬁc
molecule included in the model, e.g., silencing Smad7 by an
siRNA knockdown. The predicted PSmad1 and PSmad2
behaviors for the two groups when Smad7 is silenced are
shown in Fig. 8. This is particularly interesting since the two
solution groups exhibit very different behaviors. Again, the
unchanged PSmad1 behavior of group 1 shows that these
solutions do not need the Smad7 feedback to achieve a
transient signal. The prediction for the feedback model is
dependent on the assumption that Smad7 is the I-Smad
active in endothelial cells, which is based on experiments.
Smad6 could potentially also be active although there is no
FIGURE 4 (Left panel) Experimental
data from Western blot analysis for the
control experiment (A) and the cyclohex-
amide experiment (B) (adapted from (10)).
(C) Additional measurements of the control
experiment to illuminate the early behavior
of the pathway. (Middle panel) An average
area intensity in the inverted image is used
as a measure of relative concentration
levels. These are given relative to the actin
level measured in the cell, and normalized
to a maximal value equal to 1 (see Appen-
dix for details). (Right panel) Simulation
results. Concentrations of PSmad1 and
PSmad2 as functions of time for the control
experiment (A) and cyclohexamide-treated
systems (B) (Experiments I and II in
Materials and Methods). The curves with
error bars correspond to averages and
standard deviations for the ensemble of
model solutions resulting from ﬁtting to the
data (227 solutions in total).
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data for Smad6 behavior in endothelial cells. In other cell
types, Smad6 has been shown to be more moderately and
transiently induced by TGF-b compared to Smad7 (21,22).
A fair assumption would be that if Smad6 is induced in en-
dothelial cells its behavior would resemble the Smad7 behav-
ior, which would lead to similar behavior for a model including
Smad6 in all previous experiments but not for the Smad7
knockdown experiment. Instead, the effect of Smad7 knock-
down would be less pronounced in such a feedback model.
Robustness
To further illuminate differences between the two groups of
solutions, we computed the sensitivity as deﬁned in Eq. 3. In
Fig. 9, the sensitivity of the two groups are shown, where the
summed derivatives of PSmad1 and PSmad2 with respect to
the parameters for Experiments I and II are displayed. It is
clear that the group using the Smad7 feedback loop (group 2)
is more robust than the other group. A Wilcoxon two-sample
test on the measure +
j
sj for the solutions in the two
groups gives a p-value ,106. The largest difference is
found in the parameters governing the production and
degradation of Smad1 and Smad4 (parameters p2–p5). This
indicates that group 1 uses Smad1 and Smad4 production
and degradation to achieve the transient PSmad1 signal
instead of using the negative feedback of Smad7. It is indeed
very interesting that the transient signal can be achieved by a
FIGURE 5 Dose-response model predictions of PSmad1 (A) and PSmad2
(B) concentrations, respectively. Doses scaled to the one used for the
experiments in Fig. 4. Also shown are the corresponding measurements
taken after 45 min (adapted from (9)). The 1, n, and the 3 symbols refer
to the experimental data points after 45 min for 0.025, 1.0, and 5.0 ng/ml,
respectively. The time series show the corresponding predictions from the
ensemble with standard deviations.
FIGURE 6 (A) Hierarchical clustering analysis of the solutions deter-
mined from Experiments I and II (see Fig. 4) subject to the constraints that
R, 0.01 and that the dose experiments in Fig. 5 are well predicted (see text).
The left branch (group 1) corresponds to solutions where the Smad7
feedback loop is not used, while the right branch (group 2) uses the Smad7
feedback loop. (B) Results from PCA with the grayscale referring to the
groups found in the K-means clustering. The group on the left is group
1 (shaded) and the one on the right is group 2 (solid). The crosses are the two
cluster centers found by K-means clustering using a squared Euclidean
metric. The arrows refer to the two solutions where the clustering algorithms
disagree; these solutions have been left out in the further analysis.
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pathway with fewer molecular players, but it appears that the
drawback for the cells would be that the levels and
production/degradation rates for the Smad1 and Smad4
need to be tightly regulated to achieve a robust signal
behavior. In contrast to this, the group that uses the Smad7
feedback shows a low sensitivity in respect to Smad4 levels
(p4,p5), and more or less no sensitivity at all to Smad1 levels
(p2,p3). This latter fact, and the lack of sensitivity toward
changes of the Michaelis-Menten constant in the phospho-
rylation step (p16), indicates that the Smad1 levels are
saturated. A more detailed look at the parameter values and
Smad1 levels reveals that all solutions in group 2 indeed
have saturated levels of Smad1 (data not shown), which
hence can be regarded as a prediction of the model using
Smad7 feedback.
Group 1 is insensitive to perturbations in all parameters
directly included in the Smad7 feedback pathway (p10–p12,
p27, p28, p31, p32), which agrees with the conclusion that the
feedback is not used by these solutions. Group 2, on the other
hand, shows some sensitivity in these parameters except for
the parameters included in the Smad7 feedback on the
activated ALK5 receptor (p31, p32). Neither of these solution
ensembles make use of a Smad7 feedback for regulating
PSmad2 levels, and this part of the network could have been
left out of the model, at least for explaining the current
experiments (compare to (10)).
The most sensitive parameters in group 2 are p1, p9, p15,
p17, p22, and p24, and group 1 is about equally sensitive to
these parameters. These parameters govern the initial ALK1
and ALK5 levels (p1, p9), as well as the rates of phospho-
rylation and dephosphorylation of Smad1 (p15, p17) and
Smad2 (p22, p24). The early PSmad1 and PSmad2 kinetics
and (at least partly) the entire PSmad signal are also
dependent on these parameters. Hence, it is expected that the
ﬁtting to our kinetic PSmad1 and PSmad2 data is sensitive to
these parameters. A ﬁnal note is that although the ALK1 and
ALK5 levels are important, the production and degradation
rates are not (p0, p9). A more detailed look at the parameter
levels show that these rates are low (data not shown), and it
appears that it is the initial values that are important for the
model to explain data.
Permuting the experiments for the calibration
To further analyze the model behavior we also permuted the
experiments used for calibration. We used combinations
including the control experiment in the calibration part
since this is the only experiment where all the parameters
FIGURE 7 (A) Data and model predic-
tions of PSmad1 and PSmad2 concentra-
tion when the cells are treated with the
proteasome inhibitor MG-132, which is
modeled by removing the proteasomal
degradation of all proteins (Experiment
III). The solutions used are those of group
1 and group 2, as deﬁned by the clustering
(see Fig. 6). (B) Data and model predictions
of PSmad1 and PSmad2 concentrations
when the cells are treated with the phos-
phatase inhibitor orthovanadate, which is
modeled by removing the phosphatases
(Experiment IV), with the same grouping
as in panel A. The time series show the
predictions from the two ensembles with
standard deviations. All data are adapted
from Valdimarsdottir et al. (10).
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are present. Also, here we applied the dose experiment as
a ﬁltering step after optimization. The two additional
calibration sets used were optimization on control (I) and
MG-132 (III), and on control (I) and orthovanadate (IV)
experiments. The new parameter sets are presented in a
PCA-plot in Fig. 10 together with the previously deﬁned
parameter sets.
When optimization is performed on control and orthova-
nadate, the extracted solutions behave very similarly to the
ones extracted from optimization on control and cyclo-
hexamide (see Supplementary Material, Fig. S4). All these
solutions use the Smad7 feedback in the process of
truncating the PSmad1 signal, which is expected since the
optimization includes the orthovanadate experiment, which
mainly affects the feedback. Also, the robustness analysis on
this new data set shows a very similar pattern as for the
previously deﬁned Group 2 (data not shown).
In the case of optimizing against the control and MG-132,
the optimization procedure works less efﬁciently. Among the
solutions provided by the algorithm, only a very few resulted
in R , 0.01 and among those, none passed the ﬁltering step
against the dose experiment (see Appendix for details). The
parameter sets from this case provided in Fig. 10 are
FIGURE 8 Predictions of PSmad1 and PSmad2 concentrations when
silencing Smad7 using the solutions of group 1 and 2, respectively, as
deﬁned by the clustering (see Fig. 6). The time series shows the predictions
from the two ensembles with standard deviations.
FIGURE 9 Sensitivity analysis using derivatives of the PSmad1 and
PSmad2 concentration with respect to the different parameters of the model.
The sensitivity measure (Eq. 3) is represented on the y axis, where Group 1 is
above the x axis (positive direction upwards) and Group 2 is below the x axis
(positive direction downwards). Group 2, which uses the Smad7 feedback
loop, is found to be more robust than Group 1. The ﬁgure shows group
averages with estimated errors.
FIGURE 10 PCA plot of solutions found when different experiments are
used for optimization. The straight line separates the ones that are using the
Smad7 feedback loop (right) from those that do not (left) (see Supplemen-
tary Material, Fig. S4).
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solutions with R , 0.015, which pass the dose experiment
ﬁlter. These solutions show an average behavior for the
PSmad1 lying in between the experimental curves for control
and MG-132, and with very small change in behavior when
protein degradation is removed (see Supplementary Mate-
rial, Fig. S4). None of the parameter sets use the Smad7
feedback, and therefore these provide a poor prediction of
the orthovanadate experiment, while the predictive power
is small for the cyclohexamide experiment since the behavior
is very spread out. An interesting note is that this appar-
ent conﬂict for explaining the MG-132 together with the
other experiments can be used to direct improvements for
the model. This is illustrated by a slight adjustment of the
model perturbation for the MG-132 experiment where a
decreased inactivation of the activated receptors is included
(simulating reduced ubiquitin-dependent degradation), which
leads to an improved behavior (see Supplementary Material,
Fig. S5).
CONCLUSIONS AND OUTLOOK
We have developed a mathematical model for the TGF-b
pathway in endothelial cells and introduced novel compu-
tational procedures for ﬁnding and analyzing robust models.
This system was chosen given its paramount importance in
diseases like cancer and in developmental processes, even
though the information about concentrations, reaction rates,
and other parameters is scarce. To cope with the latter, we
generate an ensemble of solutions rather than a single one
when ﬁtting to the data. This also means that we are less
sensitive to noise and, as it turned out, we are able to identify
different solution categories with associated biological
interpretations. We use different kinetic data sets by varying
conditions including knockdowns. Some of the data sets
already exist and others are newly generated and are pre-
sented here for the ﬁrst time. Having access to kinetic data
under different conditions enables us to ﬁt models to a subset
of these and use the remaining sets for blind-test evaluations.
Our results can be summarized as follows:
With efﬁcient ODE solvers and a powerful optimization
method, simulated tempering (ST), good solutions are
found to the calibration sets.
The calibrated solutions are found to well reproduce
blind-test experiments, including those in which the
external dosage is varied.
The resulting solutions are analyzed with unsupervised
clustering methods. Two clusters emerge—one in
which the Smad7 feedback loop is employed, and
another in which it is not. The group using the Smad7
feedback is better at predicting the blind-test experi-
ments.
The robustness is investigated with a gradient method. It
is found that the solutions corresponding to the cluster
using the Smad7 feedback loop are less sensitive to
parameter perturbations, indicating that a role for this
loop is to provide robustness to the system.
Permutation of the experiments used for optimization
resulted in similar solution sets, but also highlighted
the MG-132 experiment as somewhat conﬂicting for
the model to solve. This can be used to direct im-
provements of the model, which is indicated by sim-
ulations adjusting the interpretation of the MG-132
experiment.
In our robustness analysis we have investigated how the
dynamical levels of different PSmads change for different
parameter perturbations. The PSmads represent the signal
through the pathway, but perhaps a more biologically
relevant measure is the robustness in cell response. Hence,
in the future one should augment the PSmad concentration
measurements with downstream gene expression data and
perform an integrated analysis. In this context, one should
also include the effects from cross talk with neighboring
pathways that are part of the TGF-b family.
Very recently, a detailed model for receptor dynamics was
introduced in the context of the TGF-b pathway (5). It does
not target endothelial cells speciﬁcally, but presents a
detailed study of receptor dynamics including internalization
and a speciﬁc inactivation of the ligand-bound receptor com-
plex by degradation. This model is sufﬁcient to explain a tran-
sient signal for PSmad2 after sustained TGF-b stimulation.
To relate this to our more simplistic receptor model, not
explicitly including receptor recycling, we showed that our
receptor model has as versatile activation pattern when a sin-
gle ligand is presented to the receptor. The behavior of PSmad1
in endothelial cells when treated with cyclohexamide is to
extend the signal, while the same treatment in HaCaT cells
has been shown to shorten the PSmad2 signal (23). Although
the detailed receptor model predicts a shortened activation at
cyclohexamide treatment (see Supplementary Material, Fig.
S1) in full agreement with the PSmad2 data, our full pathway
model can indeed explain the PSmad1 behavior in cyclo-
hexamide-treated endothelial cells.
From the behavior of our different solution groups, we
argue for a model where there exists a feedback from TGF-b
induced Smad7 to repress the PSmad1 activation. This is
based on indications from several experiments, which are all
reproduced by the feedback model. Needless to say, a more
distinct test of this model would be to perform a dedicated
knockdown experiment for Smad7, which is currently in
progress in siRNA experiments targeting Smad7. In this
context, the importance of Smad6 in endothelial cells also
needs to be investigated.
Our approach is not restricted to systems where all
parameter values can be experimentally estimated. Rather, it
allows for several solutions to solve a problem, and can
account for similarities in behavior of highly conserved
modules such as the TGF-b pathway, although quantitative
details differ. In this study we are conﬁned to experimental
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data which has not been calibrated to units of concentration.
This lack of knowledge propagates to our parameters. Also,
the measurements are restricted to a few components, and we
have therefore chosen a simplistic description of some of the
reactions. Hence, we have focused on relevant biological
behavior of the measured molecules for different conditions
and not attempted to evaluate parameter values with respect
to biologically reasonable ones, which would have been
dependent on further assumptions. Additional experiments,
which provide quantitative estimates of parameters and con-
centration levels, are important and will constrain the solu-
tion space for the models. On the other hand, we demonstrate
that the models, can pinpoint experiments that will provide
maximal information given the current knowledge, and the
combination of experiments and modeling provides an ef-
fective methodology for an increased understanding of
highly complex biological networks.
APPENDIX
Experimental data
All the experimental data originate from Western Blot Analysis, where we
measure the average intensity in a square on the inverted blot-images and use
these intensities as a relative measure of concentration. As it turns out, the
size of the square has only a marginal effect on the estimated concentration
levels. The concentrations are normalized with the actin level measured in
the cell, which is fairly constant throughout the time series. Finally, the
concentrations are normalized to give a maximum value of 1 for both
PSmad1 and PSmad2.
Solving the systems of ODEs
In Table 2 we show the system of ODEs used in our calculations, in which
the following assumptions are made in the calibration process:
1. The TGF-b level is constant throughout the time series.
2. At t ¼ 0, we have
P1ð0Þ ¼ T1ð0Þ ¼ P2ð0Þ ¼ P14ð0Þ ¼ P24ð0Þ
¼ T1ð0Þ ¼ T5ð0Þ ¼ T1Pð0Þ ¼ T5Pð0Þ ¼ 0: (A1)
3. The system is in equilibrium at t ¼ 0 (for zero TGF-b level), which with
Eq. A1 leads to
A1ð0Þ ¼ 1=p1; S1ð0Þ ¼ 1=p3; S4ð0Þ ¼ 1=p5;
S2ð0Þ ¼ 1=p7; A5ð0Þ ¼ 1=p9:
(A2)
The ODEs are solved using mainly the ﬁfth-order Runge-Kutta method, but
in stiff regions of parameter space we switch to the Rosenbrock method
using an adaptive procedure. For details on the ODE solvers, see Press et al.
(17).
Parameter estimation
For generating ensembles of solutions we use simulated tempering, where
conﬁgurations are generated for different ﬁctitious temperatures Tj and the
system is allowed to move between the different Tj-values. In other words, at
a given Monte Carlo step, one updates the system by swapping conﬁgu-
rations of the systems, or alternatively trading two temperatures. The method
amounts to simulating the joint probability distribution
Pðp; jÞ} expð2gj2RðpÞ=TjÞ; (A3)
where the ‘‘energy’’ R(p) is the error measure of Eq. 2 with its system
parameters p ¼ ðp1; . . . ; pK). The algorithm parameters gj govern the
weights pj of the different temperatures, Tj. The latter are chosen according
to
Tj ¼ TminðTmax=TminÞðj21Þ=ðJ21Þ; j ¼ 1; 2; . . . ; J; (A4)
where we used J ¼ 20, T1 ¼ Tmin ¼ 0.0025, and T20 ¼ Tmax ¼ 0.005. We
want to spend roughly the same amount of time on each of the temperatures,
and thus have to choose our gj-values accordingly, i.e., we want to choose
our g9j-values such that the weights, pj, are equal for all j. This is done
through trial simulations in a two-step process. First we calculate rough
estimates of the average ‘‘energy’’ at each temperature, ÆRæj and put g20 ¼ 0
and gj21 ¼ gj 2 ÆRæj(1/Tj21 2 1/Tj). In the next step, we perform longer
simulations to obtain good estimates of the weights pj; the uniform
distribution is then obtained by replacing gj with gj 1 ln pj (7).
The parameters are updated one at a time with pi / rpi, where r is a
multiplicative factor (r¼ 1.1 is used) and in 50% of the cases we set r/1=r.
At T¼ Tmin, r is allowed to vary freely in the range r 2 [1:2] individually for
each parameter, to keep the acceptance ratio above 50%. Updates are
accepted according to Eq. A3. For each K number of attempted parameter
updates, K being the number of parameters, we attempt one update to an
adjacent temperature Tj61 with a probability also governed by Eq. A3.
The performance of the algorithm is displayed in the table below showing
the number of simulations it takes on average to ﬁnd a minimum (middle
panel) and the percentage of these minima having R, 0.01 (right panel) for
each of the three sample permutations. These results can be compared with for
example (24) where different optimization algorithms including simulated
annealing are compared. The poor performance on the control1MG-132 set
is discussed in the text and in the Supplementary Material (see Table 3).
Calibration
In the ﬁrst step we merely select for solutions p satisfying R(p) , 0.01. In
the second step we also require the solutions to display the saturating
behavior observed in Experiment V. This is achieved by only considering
solutions p* satisfying
1
N
1
M
+
5:0
C¼2:5
+
tN
t¼t1
+
M
i¼1
ðxðCÞi ðt; pÞ2xð1Þi ðt;pÞÞ2, e; (A5)
where x
ðCÞ
i ðt;pÞ denotes the concentration of molecule i at time t given
the parameters p* and an initial concentration of TGF-b of C ng/ml. For
the cutoff value e we found e ¼ 0.05 to be appropriate.
Implementation
The calibration framework as well as the robustness analysis are
implemented in C11. For the two clustering methods, K-means and
TABLE 3
Sample No. of simulations R , 0.01
Control1cyclohexamide 38,919 6 5872 32.9%
Control1orthovanadate 26,783 6 4707 25.6%
Control1MG-132 33,374 6 3326 1.4%
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hierarchical clustering, and for the PCA, we used MatLab implementations
(The MathWorks, Natick, MA) corresponding to the MatLab functions
dendrogram, kmeans, and princomp, respectively.
SUPPLEMENTARY MATERIAL
An online supplement to this article can be found by visiting
BJ Online at http://www.biophysj.org.
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